Notícias

Pfizer has a 6.8% yield at a time when the market's yield is roughly 1%: Is there something wrong?

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Income seekers shouldn't give up on the stock yet.

Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.

Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.

Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]

Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

(Bloomberg) -- President Donald Trump’s threat of 100% tariffs against generic medicines is a major expansion of a strategy he’s been using against the pharmaceutical industry since his second term began. Most Read from BloombergTrump’s 100% Generic Drug Duty Threatens US Low-Cost SupplyApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesTrump Extends Pardons to Companies, Echoing a 17th Century KingSpaceX Set to Unlock $116 Billion in Shares After IPO Restrictions LiftKrem

A pharmaceutical giant is on an incredible run fueled by blockbuster drugs, forcing investors to ask if the price of admission already accounts for the entire victory lap.

Healthcare is quietly stealing the spotlight from mega cap tech in 2026, and two S&P 500 giants are trading at valuations that suggest the market has not caught on yet.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

This pharma giant is grabbing headlines, but its real value for your portfolio lies in how it moves on the market's worst days.

Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.

Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.

In the latest trading session, Pfizer (PFE) closed at $24.75, marking a -1.2% move from the previous day.

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

It is definitely a strong contender.

Pfizer is a highly respected drug company facing normal industry headwinds.

Pfizer's dividend yield is 7% for a very good reason: investors are worried about the risk of a dividend cut.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

When a regular paycheck disappears in retirement, the stakes of every investment decision skyrocket. These five high-yield stocks earning 6% or more are winning over Boomers who refuse to let rising prices eat their savings alive.

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.